| Mitchell W Mcgarrh, CRNA | |
|
2510 Lakeland Dr, Flowood, MS 39232-9513 | |
| (601) 355-1234 | |
| (601) 326-3566 |
| Full Name | Mitchell W Mcgarrh |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 23 Years |
| Location | 2510 Lakeland Dr, Flowood, Mississippi |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1871530709 | NPI | - | NPPES |
| 00126832 | Medicaid | MS | |
| P00809213 | Other | MS | MEDICARE RAILROAD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | R853598 (Mississippi) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Gastrointestinal Associates Pa | 5294795241 | 90 |
News Archive
Lightlake Therapeutics Inc., a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that results of the Company's Phase II clinical trial of its nasal spray treatment for Binge Eating Disorder were presented at the American Psychiatric Association Annual Meeting in San Francisco by Professor Hannu Alho, MD, professor of addiction medicine at the University of Helsinki and Principal Investigator for the trial.
A genetically engineered clotting factor that controlled hemophilia in an animal study offers a novel potential treatment for human hemophilia and a broad range of other bleeding problems.
Cell Therapeutics, Inc. (CTI) announced today that its new class of platinum-based anti-tumor compounds, termed bis-platinates, demonstrated a stronger anti-tumor potency and activity compared to currently available platinum-based compounds as well as the ability to overcome cisplatin-resistance in cancer cell lines.
Scientists at Cold Spring Harbor Laboratory (CSHL) have discovered how a protein long known to be an essential activator of DNA replication actually triggers this process in cells.
A cross-sectional study by investigators from Tokyo University has found that exercising in middle age is a protective factor against sarcopenia and effective in maintaining muscle strength and physical performance.
› Verified 3 days ago
| Entity Name | Medical Foundation Of Central Mississippi Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992774814 PECOS PAC ID: 1153216411 Enrollment ID: O20040217000380 |
News Archive
Lightlake Therapeutics Inc., a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that results of the Company's Phase II clinical trial of its nasal spray treatment for Binge Eating Disorder were presented at the American Psychiatric Association Annual Meeting in San Francisco by Professor Hannu Alho, MD, professor of addiction medicine at the University of Helsinki and Principal Investigator for the trial.
A genetically engineered clotting factor that controlled hemophilia in an animal study offers a novel potential treatment for human hemophilia and a broad range of other bleeding problems.
Cell Therapeutics, Inc. (CTI) announced today that its new class of platinum-based anti-tumor compounds, termed bis-platinates, demonstrated a stronger anti-tumor potency and activity compared to currently available platinum-based compounds as well as the ability to overcome cisplatin-resistance in cancer cell lines.
Scientists at Cold Spring Harbor Laboratory (CSHL) have discovered how a protein long known to be an essential activator of DNA replication actually triggers this process in cells.
A cross-sectional study by investigators from Tokyo University has found that exercising in middle age is a protective factor against sarcopenia and effective in maintaining muscle strength and physical performance.
› Verified 3 days ago
| Entity Name | Anesthesia Consultants Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750300836 PECOS PAC ID: 4486637881 Enrollment ID: O20040608000711 |
News Archive
Lightlake Therapeutics Inc., a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that results of the Company's Phase II clinical trial of its nasal spray treatment for Binge Eating Disorder were presented at the American Psychiatric Association Annual Meeting in San Francisco by Professor Hannu Alho, MD, professor of addiction medicine at the University of Helsinki and Principal Investigator for the trial.
A genetically engineered clotting factor that controlled hemophilia in an animal study offers a novel potential treatment for human hemophilia and a broad range of other bleeding problems.
Cell Therapeutics, Inc. (CTI) announced today that its new class of platinum-based anti-tumor compounds, termed bis-platinates, demonstrated a stronger anti-tumor potency and activity compared to currently available platinum-based compounds as well as the ability to overcome cisplatin-resistance in cancer cell lines.
Scientists at Cold Spring Harbor Laboratory (CSHL) have discovered how a protein long known to be an essential activator of DNA replication actually triggers this process in cells.
A cross-sectional study by investigators from Tokyo University has found that exercising in middle age is a protective factor against sarcopenia and effective in maintaining muscle strength and physical performance.
› Verified 3 days ago
| Entity Name | Gastrointestinal Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093765604 PECOS PAC ID: 5294795241 Enrollment ID: O20041013001263 |
News Archive
Lightlake Therapeutics Inc., a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that results of the Company's Phase II clinical trial of its nasal spray treatment for Binge Eating Disorder were presented at the American Psychiatric Association Annual Meeting in San Francisco by Professor Hannu Alho, MD, professor of addiction medicine at the University of Helsinki and Principal Investigator for the trial.
A genetically engineered clotting factor that controlled hemophilia in an animal study offers a novel potential treatment for human hemophilia and a broad range of other bleeding problems.
Cell Therapeutics, Inc. (CTI) announced today that its new class of platinum-based anti-tumor compounds, termed bis-platinates, demonstrated a stronger anti-tumor potency and activity compared to currently available platinum-based compounds as well as the ability to overcome cisplatin-resistance in cancer cell lines.
Scientists at Cold Spring Harbor Laboratory (CSHL) have discovered how a protein long known to be an essential activator of DNA replication actually triggers this process in cells.
A cross-sectional study by investigators from Tokyo University has found that exercising in middle age is a protective factor against sarcopenia and effective in maintaining muscle strength and physical performance.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mitchell W Mcgarrh, CRNA 2510 Lakeland Dr, Flowood, MS 39232-9513 Ph: (601) 355-1234 | Mitchell W Mcgarrh, CRNA 2510 Lakeland Dr, Flowood, MS 39232-9513 Ph: (601) 355-1234 |
News Archive
Lightlake Therapeutics Inc., a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today that results of the Company's Phase II clinical trial of its nasal spray treatment for Binge Eating Disorder were presented at the American Psychiatric Association Annual Meeting in San Francisco by Professor Hannu Alho, MD, professor of addiction medicine at the University of Helsinki and Principal Investigator for the trial.
A genetically engineered clotting factor that controlled hemophilia in an animal study offers a novel potential treatment for human hemophilia and a broad range of other bleeding problems.
Cell Therapeutics, Inc. (CTI) announced today that its new class of platinum-based anti-tumor compounds, termed bis-platinates, demonstrated a stronger anti-tumor potency and activity compared to currently available platinum-based compounds as well as the ability to overcome cisplatin-resistance in cancer cell lines.
Scientists at Cold Spring Harbor Laboratory (CSHL) have discovered how a protein long known to be an essential activator of DNA replication actually triggers this process in cells.
A cross-sectional study by investigators from Tokyo University has found that exercising in middle age is a protective factor against sarcopenia and effective in maintaining muscle strength and physical performance.
› Verified 3 days ago
Miss Amy Lauren Steele, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1026 N Flowood Dr, Flowood, MS 39232 Phone: 601-454-2401 Fax: 601-936-9971 | |
Michael Brian Nobles, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2510 Lakeland Dr, Flowood, MS 39232 Phone: 601-355-1234 Fax: 601-326-3566 | |
Aimee Renaudin, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 1030 River Oaks Drive, Flowood, MS 39232 Phone: 334-279-1450 Fax: 334-279-1660 | |
Nina E. Mclain, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2510 Lakeland Dr, Flowood, MS 39232 Phone: 601-355-1234 Fax: 601-326-3559 | |
Karen Lynne Whitwer, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 2550 Flowood Dr, Suite 400, Flowood, MS 39232 Phone: 601-933-9521 Fax: 601-933-9525 | |
Brittany O'steen Morrow, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2510 Lakeland Dr, Flowood, MS 39232 Phone: 601-355-1234 Fax: 601-352-4882 | |
Lacey W Whittington, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1026 N Flowood Dr, Flowood, MS 39232 Phone: 601-932-1000 |